| scholarly article | Q13442814 |
| P50 | author | Stanley Plotkin | Q7599873 |
| P2093 | author name string | Laurent Coudeville | |
| Françoise Weber | |||
| Philippe Andre | |||
| Fabrice Bailleux | |||
| P2860 | cites work | Vaccines for preventing influenza in the elderly | Q24245325 |
| Vaccines for preventing influenza in healthy adults | Q24245429 | ||
| Serologic studies of acute respiratory infections in military personnel | Q27487427 | ||
| A call to cellular & humoral arms: enlisting cognate T cell help to develop broad-spectrum vaccines against influenza A. | Q30368604 | ||
| Relationship between haemagglutination-inhibiting antibody titres and clinical protection against influenza: development and application of a bayesian random-effects model | Q33538308 | ||
| Haemagglutination-inhibiting antibody to influenza virus | Q35747515 | ||
| A one-year study of trivalent influenza vaccines in primed and unprimed volunteers: immunogenicity, clinical reactions and protection | Q36249751 | ||
| Immunity to attenuated influenza virus WRL 105 infection induced by heterologous, inactivated influenza A virus vaccines | Q36251063 | ||
| A graded-dose study of inactivated, surface antigen influenza B vaccine in volunteers: reactogenicity, antibody response and protection to challenge virus infection | Q36258297 | ||
| A comparison of live and inactivated influenza A (H1N1) virus vaccines. 1. Short-term immunity | Q36258475 | ||
| A comparison of live and inactivated influenza A (H1N1) virus vaccines. 2. Long-term immunity | Q36258488 | ||
| Vaccines: correlates of vaccine-induced immunity | Q37193062 | ||
| Field trial with human and equine influenza vaccines in children: protection and antibody titres | Q40800794 | ||
| Inactivated influenza vaccines. 2. Laboratory indices of protection | Q41243525 | ||
| Surrogate endpoints in clinical trials: definition and operational criteria | Q41310696 | ||
| Influenza vaccines. A reappraisal of their use. | Q41676828 | ||
| The role of serum haemagglutination-inhibiting antibody in protection against challenge infection with influenza A2 and B viruses | Q42790878 | ||
| Artificially induced Asian influenza in vaccinated and unvaccinated volunteers | Q43209872 | ||
| Evaluation of monovalent influenza virus vaccines. I. Observations on antibody response following vaccination | Q45684328 | ||
| Seroprotection rate, mean fold increase, seroconversion rate: which parameter adequately expresses seroresponse to influenza vaccination? | Q47428977 | ||
| A framework for assessing immunological correlates of protection in vaccine trials | Q48689937 | ||
| Intradermal influenza vaccine administered using a new microinjection system produces superior immunogenicity in elderly adults: a randomized controlled trial. | Q51119752 | ||
| Intradermal influenza vaccine for older adults: a randomized controlled multicenter phase III study. | Q51137993 | ||
| On the relationship between mean antibody level, seroprotection and clinical protection from influenza. | Q51779289 | ||
| Comparison of influenza serological techniques by international collaborative study. | Q53384986 | ||
| An outbreak of an influenza type A variant in a closed population: The effect of homologous and heterologous antibody on infection and illness | Q57116214 | ||
| Influenzavirus infections in Seattle families, 1975-1979. II. Pattern of infection in invaded households and relation of age and prior antibody to occurrence of infection and related illness | Q70443341 | ||
| An outbreak of influenza A2 in a population with a known antibody profile | Q72824599 | ||
| Antibody efficacy as a keen index to evaluate influenza vaccine effectiveness | Q73598399 | ||
| A model for immunological correlates of protection | Q81204629 | ||
| T cell responses are better correlates of vaccine protection in the elderly | Q83276474 | ||
| P433 | issue | 10 | |
| P921 | main subject | influenza vaccine | Q383260 |
| P304 | page(s) | 841-848 | |
| P577 | publication date | 2010-10-01 | |
| P1433 | published in | Hum Vaccin | Q15755183 |
| P1476 | title | A new approach to estimate vaccine efficacy based on immunogenicity data applied to influenza vaccines administered by the intradermal or intramuscular routes | |
| P478 | volume | 6 |
| Q36363243 | A Novel Dynamic Model for Health Economic Analysis of Influenza Vaccination in the Elderly |
| Q40527989 | A phase 1, open-label, randomized study to compare the immunogenicity and safety of different administration routes and doses of virosomal influenza vaccine in elderly |
| Q94106259 | Addendum to the 2010-2011 Seasonal Trivalent Inactivated Influenza Vaccine: Recommendations on the use of intradermal trivalent inactivated influenza vaccine (TIV-ID) |
| Q55085613 | Age- and risk-related appropriateness of the use of available influenza vaccines in the Italian elderly population is advantageous: results from a budget impact analysis. |
| Q48504278 | Cost-effectiveness analysis of different seasonal influenza vaccines in the elderly Italian population |
| Q30578344 | Design and data analysis of experimental trials to test vaccine candidates against zoonotic pathogens in animals: the case of a clinical trial against campylobacter in broilers |
| Q37375954 | Fluzone® intra-dermal (Intanza®/Istivac® Intra-dermal): An updated overview |
| Q64276594 | HAI and NAI titer correlates of inactivated and live attenuated influenza vaccine efficacy |
| Q30385397 | Influenza immunology evaluation and correlates of protection: a focus on vaccines. |
| Q30418015 | Microneedle and mucosal delivery of influenza vaccines |
| Q35910629 | Pes Anserine Bursitis in Symptomatic Osteoarthritis Patients: A Mesotherapy Treatment Study |
| Q40143562 | Rationale for two influenza B lineages in seasonal vaccines: A meta-regression study on immunogenicity and controlled field trials |
| Q30381595 | Refining the approach to vaccines against influenza A viruses with pandemic potential. |
| Q35986424 | Role of mesotherapy in musculoskeletal pain: opinions from the italian society of mesotherapy. |
| Q30363877 | Summary of knowledge gaps related to quality and efficacy of current influenza vaccines. |
| Q91449694 | Updates on immunologic correlates of vaccine-induced protection |
Search more.